Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Luis Usuga

Obstetrics & Gynecology Rockwall, TX Medical Doctor

NPI 1336214048 CMS profile 60316

6800 Heritage Pkwy Ste 102, Rockwall, TX 75087

Open in the dashboard

General payments

$29,124

188 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Luis Usuga of Rockwall, TX is reported in the CMS Open Payments database as having received $29,124 across 188 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,721 25
2024 General $354 16
2023 General $571 28
2022 General $390 18
2021 General $806 43
2020 General $21,434 26
2019 General $847 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Luis Usuga
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Luis Usuga were reported at $4,721. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Luis Usuga Obstetrics & Gynecology median Middle half National median
2019 $847 $172 $62–$391 $163
2020 $21,434 $94 $36–$222 $114
2021 $806 $136 $42–$369 $132
2022 $390 $160 $50–$433 $149
2023 $571 $169 $56–$423 $160
2024 $354 $152 $50–$371 $164
2025 $4,721 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $21,089 5 payments
  2. Intuitive Surgical, Inc. $2,709 8 payments
  3. Coloplast Corp $1,541 9 payments
  4. MIMEDX Group, Inc. $616 2 payments
  5. AbbVie, Inc. $534 36 payments
  6. Exeltis, USA Inc. $531 27 payments
  7. Millicent US Inc $262 7 payments
  8. VIVUS, Inc. $204 13 payments
  9. Novo Nordisk Inc $203 12 payments
  10. Mayne Pharma Inc. $191 8 payments
  11. Other $1,245 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Gift $21,024 1 payment
  2. Food and Beverage $3,568 174 payments
  3. Travel and Lodging $2,239 9 payments
  4. Education $1,693 3 payments
  5. Consulting Fee $600 1 payment
Products named General payments · program years 2019–2025
  1. LILETTA $21,026 2 payments
  2. DAVINCI XI $1,500 1 payment
  3. Da Vinci Surgical System $1,209 7 payments
  4. Altis Women's Health $752 4 payments
  5. Aris $452 1 payment
  6. LO LOESTRIN FE $336 23 payments
  7. ALTIS Female Incontinence $328 2 payments
  8. ORILISSA $324 22 payments
  9. SLYND $314 15 payments
  10. ORIAHNN $268 18 payments
  11. Other $2,378 131 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

40

Median for Obstetrics & Gynecology: 65

Drug cost

$1,508

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

55%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 18 $1,023
Progesterone Progesterone, Micronized Brand 22 $485

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $38
$38 — —
SLYND
  • Exeltis, USA Inc. $35
$35 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $23
  • PFIZER INC. $8
$32 — —
Veozah
  • Astellas Pharma US Inc $23
$23 — —
DUAVEE
  • PFIZER INC. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record